Cybin Inc. Secures $30M in Private Placement

Ticker: HELP · Form: 6-K · Filed: Mar 20, 2024 · CIK: 1833141

Cybin INC. 6-K Filing Summary
FieldDetail
CompanyCybin INC. (HELP)
Form Type6-K
Filed DateMar 20, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentbullish

Sentiment: bullish

Topics: funding, clinical-trials, press-release

TL;DR

Cybin just raised $30M to fund its psychedelic drug trials. Big news for their pipeline.

AI Summary

Cybin Inc. filed a Form 6-K on March 20, 2024, reporting for the month of March 2024. The filing includes a press release announcing Cybin's closing of a private placement, which is expected to provide approximately $30 million in gross proceeds. This funding is intended to support the company's ongoing clinical development programs and general corporate purposes.

Why It Matters

This significant funding infusion positions Cybin to advance its clinical trials for novel psychedelic-based therapeutics, potentially bringing new treatments to market.

Risk Assessment

Risk Level: medium — The company is in the clinical development phase for novel therapeutics, which carries inherent scientific and regulatory risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of the $30 million in gross proceeds?

The proceeds are intended to support Cybin's ongoing clinical development programs and general corporate purposes.

When was this Form 6-K filed?

The Form 6-K was filed on March 20, 2024.

Who signed the report on behalf of Cybin Inc.?

Doug Drysdale, Chief Executive Officer, signed the report.

What type of company is Cybin Inc. classified as by the SEC?

Cybin Inc. is classified under Standard Industrial Classification: Pharmaceutical Preparations [2834].

What is the principal executive office address for Cybin Inc.?

The principal executive office is located at 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9.

Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-03-20 15:16:14

Filing Documents

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date March 20, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 Cybin Announcement Press Release 99.2 Cybin Closing Press Release

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing